Drug Trial Radar · NCT07096193
Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus
Last checked: Nov 20, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Jul 31, 2025
Primary completion
Jan 2030
Study completion Jan 2030
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Jul 31, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 69 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goals of this clinical study are to first learn more about safety and dosing of the study drug GS-4321 in healthy participants. The study will then learn about the safety and effectiveness of GS-4321 in participants with chronic hepatitis delta (CHD). The primary objective of Phase 1 of this study is to evaluate the safety, tolerability and Pharmacokinetics (PK) of the escalating single doses of GS-4321 administered in healthy participants. The primary objective of Phase 2 of this study is to evaluate the efficacy and safety of the multiple escalating doses of GS-4321 in participants with CHD.
Conditions
- Chronic Hepatitis Delta
Interventions
GS-4321Drug
Administered subcutaneous (SC) or intravenously IV
GS-4321 PlaceboDrug
Administered SC
GS-4321Drug
Administered SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1 and 2: Percentage of Participants With Treatment-emergent Adverse EventsTime frame: Phase 1: First dose up to 44 weeks; Phase 2: First dose up to 96 Weeks plus 48 weeks of posttreatment follow-up
- Phase 1 and 2: Percentage of Participants With Treatment-emergent Serious Adverse EventsTime frame: Phase 1: First dose up to 44 weeks; Phase 2: First dose up to 96 Weeks plus 48 weeks of posttreatment follow-up
- Phase 1 and 2: Percentage of Participants Experiencing Treatment-emergent Clinical Laboratory AbnormalitiesTime frame: Phase 1: First dose up to 44 weeks; Phase 2: First dose up to 96 Weeks plus 48 weeks of posttreatment follow-up
- Phase 1: Serum Pharmacokinetic (PK) parameter; AUC of GS-4321Time frame: First dose up to 24 Weeks
- Phase 1: Serum PK Parameter: CmaxTime frame: First dose up to 24 Weeks
- Phase 1: Serum PK Parameter: TmaxTime frame: First dose up to 24 Weeks
- Phase 1: Serum PK Parameter: t1/2Time frame: First dose up to 24 Weeks
- Phase 2: Proportion of Participants with Combined ResponseTime frame: Up to 96 Weeks
Locations
28 sites in 9 countries. Site status is shown where the registry gives one.
Investigative Site
Anaheim, California · Recruiting
University of California, San Diego - Altman Clinical and Translational Research Institute
La Jolla, California · Recruiting
University of Louisville, Clinical Trials Unit
Louisville, Kentucky · Recruiting
University of Maryland, Institute of Human Virology, Clinical Research Unit
Baltimore, Maryland · Recruiting
The New York-Presbyterian Hospital
New York, New York · Recruiting
University Multi-profile Hospital for Active Treatment "SofiaMed" 00D
Sofia, Bulgaria · Recruiting
Medizinische Hochschule Hannover, Address: Klinik für Gastroenterologie, Hepatologie, Infektiologie und Endokrinologie
Hanover, Germany · Recruiting
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, SC Gastroenterologia ed Epatologia
Milan, Italy · Recruiting
IMSP Spitalul Clinic de Boli Infectioase "Toma Ciorba"
Chinsinau, Moldova · Recruiting
PMSI Clinical Republican Hospital "Timofei Mosneaga"
Chisinau, Moldova · Recruiting
Institutul National De Boli Infectioase Prof. Dr. Matei Bals
Bucharest, Romania · Recruiting
Fundatia Dr. Victor Babes
Bucharest, Romania · Recruiting
Infectious Diseases Institutul National De Boli Infectioase Prof. Matei Bals
Bucharest, Romania · Recruiting
Gastromedica S.R.L.
Iași, Romania · Recruiting
Korea University Ansan Hospital
Ansan-si, South Korea · Recruiting
The Catholic University of Korea Bucheon St. Mary's Hospital
Bucheon-si, South Korea · Recruiting
The Catholic University of Korea, Seoul St. Mary's Hospital
Seoul, South Korea · Recruiting
Samsung Medical Center
Seoul, South Korea · Recruiting
Ditmanson Medical Foundation Chia-Yi Christian Hospital
Chiayi City, Taiwan · Recruiting
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan · Recruiting
Chang Gung Medical Foundation Kaohsiung Chang Gung Memorial Hospital
Kaohsiung City, Taiwan · Recruiting
National Taiwan University Hospital
Taipei, Taiwan · Recruiting
Hacettepe University Faculty of Medicine Hospital Hacettepe Neighborhood
Ankara, Turkey (Türkiye) · Recruiting
Ankara Bilkent City Hospital Oncology Hospital Universiteler Neighborhood
Ankara, Turkey (Türkiye) · Recruiting
Ankara Bilkent City Hospital Universiteler Neighborhood, 1604th Street No: 9,
Ankara, Turkey (Türkiye) · Recruiting
Dicle University Faculty of Medicine
Diyarbakrir, Turkey (Türkiye) · Recruiting
Istabul University-Cerrahpasa Faculty of Medicine Hospital
Istanbul, Turkey (Türkiye) · Recruiting
Koc University Medical Faculty Hospital
Istanbul, Turkey (Türkiye) · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.